Model is a hypothetical patient profile, for illustrative purposes only
*Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients
†Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs. placebo.
‡Xolair® is also available as a lyophilized formulation
References: 1. Maurer M, et al. N Engl J Med 2013;368:924-935. 2. Xolair® Summary of Product Characteristics 2016. 3. Maurer M et al. Allergy 2011;66:317-330. 4. Weller K, et al. J Eur Acad Dermatol Venereol 2013;27:43-50